Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events

Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events Opinion EDITORIAL What Matters Most: the Drug, the Dose, or the Placebo? Garima Sharma, MD; Seth S. Martin, MD, MHS; Roger S. Blumenthal, MD Hypertriglyceridemia is associated with an increased risk The risk reduction observed in REDUCE-IT prompted of atherosclerotic cardiovascular disease (ASCVD), indepen- further research into protective mechanistic changes of EPA on dent of low-density lipoprotein cholesterol (LDL-C) con- atherosclerotic coronary plaque. The Effect of Vascepa trol. Standard treatment strategies have included lifestyle on Improving Coronary Atherosclerosis in People With High Tri- modification, weight and dia- glycerides Taking Statin Therapy (EVAPORATE) trial, which in- betes management, and statin cluded 80 patients aged 30 through 85 years with known coro- Editor's Note page 2280 therapy. Previous triglyceride- nary atherosclerosis and taking stable statin therapy, found that lowering trials with niacin, 4 g/d of IPE in addition to maximally tolerated statin therapy fibrates, and mixed omega-3 led to a relative reduction of 17% (−0.3 ± 1.5 mm in treatment Related article page 2268 fatty acids have not demon- group vs 0.9 ± 1.7 mm in the statin-only group,P = .006) in low- 1,2 strated consistent risk reduction of ASCVD. However, strong attenuation plaque at 18 months in patients treated with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events

JAMA , Volume 324 (22) – Dec 8, 2020

Loading next page...
 
/lp/american-medical-association/effects-of-omega-3-fatty-acids-on-major-adverse-cardiovascular-events-QvoU46iR2c
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2020.22387
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL What Matters Most: the Drug, the Dose, or the Placebo? Garima Sharma, MD; Seth S. Martin, MD, MHS; Roger S. Blumenthal, MD Hypertriglyceridemia is associated with an increased risk The risk reduction observed in REDUCE-IT prompted of atherosclerotic cardiovascular disease (ASCVD), indepen- further research into protective mechanistic changes of EPA on dent of low-density lipoprotein cholesterol (LDL-C) con- atherosclerotic coronary plaque. The Effect of Vascepa trol. Standard treatment strategies have included lifestyle on Improving Coronary Atherosclerosis in People With High Tri- modification, weight and dia- glycerides Taking Statin Therapy (EVAPORATE) trial, which in- betes management, and statin cluded 80 patients aged 30 through 85 years with known coro- Editor's Note page 2280 therapy. Previous triglyceride- nary atherosclerosis and taking stable statin therapy, found that lowering trials with niacin, 4 g/d of IPE in addition to maximally tolerated statin therapy fibrates, and mixed omega-3 led to a relative reduction of 17% (−0.3 ± 1.5 mm in treatment Related article page 2268 fatty acids have not demon- group vs 0.9 ± 1.7 mm in the statin-only group,P = .006) in low- 1,2 strated consistent risk reduction of ASCVD. However, strong attenuation plaque at 18 months in patients treated with

Journal

JAMAAmerican Medical Association

Published: Dec 8, 2020

References